Bank of New York Mellon Corp Takes Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 32,579 shares of the company’s stock, valued at approximately $740,000. Bank of New York Mellon Corp owned about 0.22% of Jasper Therapeutics at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JSPR. Opaleye Management Inc. bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at approximately $3,144,000. Kingdon Capital Management L.L.C. raised its position in Jasper Therapeutics by 16.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after purchasing an additional 500,000 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in Jasper Therapeutics during the 1st quarter valued at about $599,000. Russell Investments Group Ltd. bought a new stake in Jasper Therapeutics during the 1st quarter valued at $2,343,000. Finally, StemPoint Capital LP bought a new stake in shares of Jasper Therapeutics in the first quarter worth about $3,794,000. Institutional investors own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

JSPR has been the subject of a number of research analyst reports. BTIG Research began coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a “buy” rating and a $90.00 target price for the company. Royal Bank of Canada cut their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They set a “buy” rating and a $86.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Tuesday, August 13th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $73.00.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $23.88 on Monday. The company has a market cap of $359.73 million, a PE ratio of -4.24 and a beta of 2.22. Jasper Therapeutics, Inc. has a 52-week low of $4.00 and a 52-week high of $31.01. The firm’s 50 day moving average price is $19.75 and its 200-day moving average price is $22.69.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.12. On average, analysts forecast that Jasper Therapeutics, Inc. will post -4.16 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.